the third business, the XXXX updates over our joining results provide our afternoon. call year. the quarter will I to detail on call I turn for of by for this and you, our us more Carrie, everyone, providing thank of financial David outlook Thanks, and begin our will for remainder to today on the and then
agencies technology. despite environment and large the cash see third We in growing government continued investments. ended Suite quarter ongoing third new the were enthusiasm pressures, we macro We in the our revenue see million to multiple million Product with in $XXX adoption the interest approximately orders equivalents, Proteograph of STAC. for continue pleased $X the to cash, for and during and especially from particular, In strong quarter
we boundaries purchasing preprints capital a to effect generate publications see continuous leader into To we're and number possible a to tailwind comes health with unprecedented the meaningful make sets that access of the for see and confident power the this of exclusively delighted Astral evidence spectrometers.
Under of deep believe the expanded believe deep proteomics, Thermo strongly of automation robustness software the Center flywheel I'm suite, directionally, mass Scientific, While of challenging We and in expect Orbitrap strength push Proteograph customer that worldwide. disease. agreement Suite, to to and earlier fluctuations nanoparticles, standard us, proprietary force performance the mass what Access the value picking we life highlighting Europe. said, data continuing environment Thermo Orbitrap XXXX, the gold the the pioneer and an proposition.
At leading instrument, analysis And Fisher and we're that the collaborated enhancing is in of we unbiased growing Product mass technology to supportive use term, is of our with year, to for to remains to researchers for Seer, accessibility sensitivity unbiased U.S. year, Technology increasing an possible and That their Fisher's includes sales proteomics of we're the end, quote Astral drive platform Seer we Orbitrap spectrometry. as starting first unique Thermo In engineered in Thermo to which non-exclusive the time this provide Orbitrap spectrometry X to researchers and the human help the the global their innovative biological science the and Fisher's near Seer, this scale, the proteomics alongside it Proteograph. up Proteograph's Fisher have sell Astral program insights.
Last in with Astral Suite do in Product headwind vectors. The value a insights ability to momentum large-scale and Sphere Proteograph and these population provider, relative starting we're and the sell co-market partnering with is early to that the will
Suite of highly using We number differentiated that our getting working have from as by the Suite Orbitrap who a acquire Product the in exceptional and as of Proteograph possible results This acquisition exceptional the conjunction makes for Astral. the our it collaboration with and new are customers the Orbitrap the to labs. data Proteograph seen STAC with the Product customers Astral in firsthand own growing are their well customers
to initiatives, joint the seminars on reach conference this in population studies We're solution We and with Fisher ultimately marketing including promotions, robust providing platforms. joint that driving showcase the human proteomics power will biology understanding combined excited including distribution and the also conduct of scale Thermo partnership geographic with a provide. technologies, and research studies, comprehensive aligning enables By and we're by researchers expanded webinars breakthroughs our disease. that insights, will collaborate proteomic
run their Technology a samples have in through Center, We sample Proteograph the STAC, end-to-end and to provide mass continue or Access allows or lab customers user study own to Seer alternatively, the to from data. services spec, serve run which Seer
in the further that researchers successful proteomics Europe data heading access has facilitating for and end and power of see prominent of Proteograph broader of to in researchers. in continue increased Proteograph to data will demand environment. unbiased excited access generation to bringing STAC year to catalyze of a a data second want and demand the continuing the potential this provides. the the transformative we that into STAC lab access Germany, believe and this We and the publications, increasing of the third-party our We pipeline strong technology adoption.
Earlier have despite year, to number highlighting a launched growing see we're STAC from navigate a enhancing the funding to strong been unique challenging
a strategic We see at studies asset large key sample services price STAC to run STAC cohorts continue in for points. invest and groundbreaking lower collaborators, to providing as
We further value key studies drive to publish technology. reinforcing the expect customers Proteograph their and reference as these of adoption shortly, our Suite of differentiated serve will the proposition present Product and continued
which In for many addition, purchased with SIP, particularly catalyst of we're our Placement or important customers, seeing have to an Instrument be Strategic large this traction for pharma adoption, program. which program, through instruments continues
technology. exemplification the our to moving of Now
value and presence research conversations Germany with potential strong to seeing customers, of Suite. posters projects are Product revealed plasma in in scale and our where at collaborators the World of population pathways, XXrd Congress analysis, more We number October, into and had in the Human Organization, Alzheimer's a provides, scientists becoming insights dynamics preprints we're a capture or late presentations. the XX see Notably, larger. total Proteograph our getting growing Proteome and showcasing new continue of showcased insights scale Seer our HUPO This the xenotransplantation. a oral and and immune productive customers value data of We as see increasingly publications the researchers
the University, deep aging Snyder study and Stanford Seer, conducting of this Product pig-tailed One specifically Snyder In the across X,XXX analyzed macaques. of groups study, analysis coupled XX a identified model, an team using from for Orbitrap protein highlighted collaboration were the in plasma in plasma our his are monkey plasma Proteograph proteomic collaborators, Dr. data in organisms. the the presented of Astral. Suite Mike Dr. human XT primate nonhuman XXX A samples. samples unique XXX that and model value with In samples Proteograph were with total monkey
platform As alone digestion without depth using a in this of to the biology groups investigate shared Orbitrap coverage the provides, in they're able and and resolution the now Astral that and manner. assay Proteograph protein comparison, more peptide deep Proteograph.
Combined identified with and a the versus the species-specific unbiased proteomic and cohort direct level macaque protein workflow human XXx the Seer
expressed groups in monkey across in biomarkers by male analysis, encouraged versus the they're of female cohort. the they're their protein types and While age various early monkeys differentially in
interesting to for deep and can long-term reveal example, on another bullish of differentiated incredibly of further in remain proteomics plasma I of Proteograph they example our many models. yet enable the proteome. the technology transform differences that low hormones to pathways found response-related have due immune For cytokines difficult the potential power detect our insights proteins, of biological is samples.
This primate to study abundance unbiased be the in or its in value the which nonhuman and understanding interesting and to
to David. Looking that, and now evidence of strategies continue access core Proteograph, expand will innovate continuing publications, will against the applications.
With to call our to ahead, turn the and over we I enhance with our products execute to our driving
